Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.

Krejsa CM, Holly RD, Heipel M, Bannink KM, Johnson R, Roque R, Heffernan J, Hill J, Chin L, Wagener F, Shiota F, Henderson K, Sivakumar PV, Ren HP, Barahmand-Pour F, Foster D, Clegg C, Kindsvogel W, Ponce R, Hughes SD, Waggie K.

PLoS One. 2013 Jun 25;8(6):e67256. doi: 10.1371/journal.pone.0067256. Print 2013.

2.

Comparison of vascular leak syndrome in mice treated with IL21 or IL2.

Sivakumar PV, Garcia R, Waggie KS, Anderson-Haley M, Nelson A, Hughes SD.

Comp Med. 2013 Feb;63(1):13-21.

3.

A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.

Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV, Snavely M.

MAbs. 2010 Jan-Feb;2(1):20-34. Epub 2010 Jan 2.

4.

Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.

S√łndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ.

J Immunol. 2009 Dec 1;183(11):7326-36. doi: 10.4049/jimmunol.0902697. Epub 2009 Nov 13.

5.

Interleukin 21 enhances antibody-mediated tumor rejection.

Smyth MJ, Teng MW, Sharkey J, Westwood JA, Haynes NM, Yagita H, Takeda K, Sivakumar PV, Kershaw MH.

Cancer Res. 2008 Apr 15;68(8):3019-25. doi: 10.1158/0008-5472.CAN-07-6019.

6.

Interleukin 21: combination strategies for cancer therapy.

Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV.

Nat Rev Drug Discov. 2008 Mar;7(3):231-40. doi: 10.1038/nrd2482. Review. Erratum in: Nat Rev Drug Discov. 2008 Mar;7(3):272.

PMID:
18259184
7.

Interleukin-21 signaling: functions in cancer and autoimmunity.

Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV.

Clin Cancer Res. 2007 Dec 1;13(23):6926-32. Review.

8.

Toxicity as a result of immunostimulation by biologics.

Gribble EJ, Sivakumar PV, Ponce RA, Hughes SD.

Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):209-34. Review.

PMID:
17428152
9.

IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.

Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL.

J Immunol. 2005 Aug 15;175(4):2167-73.

10.
11.

Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.

Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D.

J Exp Med. 2003 Jun 2;197(11):1427-39.

12.

Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells.

Goldrath AW, Sivakumar PV, Glaccum M, Kennedy MK, Bevan MJ, Benoist C, Mathis D, Butz EA.

J Exp Med. 2002 Jun 17;195(12):1515-22.

13.
14.

Generation of antibodies to cell surface markers on mature natural killer cells.

Lai WC, Zhang Y, George T, Sivakumar PV, Stepp S, Zhou D, Bennett M, Kumar V, Schatzle J.

Methods Mol Biol. 2000;121:211-7. Review. No abstract available.

PMID:
10818728
15.

Hybrid resistance by mouse NK cells in vitro.

Sivakumar PV, George T, Puzanov IJ, Williams NS, Stepp S, Liu J, Schatzle J, Lai WC, Bennett M, Kumar V.

Methods Mol Biol. 2000;121:73-9. Review. No abstract available.

PMID:
10818718
16.

Murine natural killer cells and hybrid resistance to hemopoietic cells in vivo.

Liu J, George T, Devora GA, Sivakumar PV, Davenport C, Lai WC, Schatzle J, Kumar V, Bennett M.

Methods Mol Biol. 2000;121:61-71. Review. No abstract available.

PMID:
10818717
17.

Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells.

Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Bennett M, Kumar V.

J Immunol. 1999 Sep 1;163(5):2648-56.

18.

Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development.

Sivakumar PV, Gunturi A, Salcedo M, Schatzle JD, Lai WC, Kurepa Z, Pitcher L, Seaman MS, Lemonnier FA, Bennett M, Forman J, Kumar V.

J Immunol. 1999 Jun 15;162(12):6976-80.

19.

Development of self-recognition systems in natural killer cells.

Sivakumar PV, Williams NS, Puzanov IJ, Schatzle JD, Bennett M, Kumar V.

Adv Exp Med Biol. 1998;452:1-12. Review.

PMID:
9889953
20.

Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems.

Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Schatzle JD, Bennett M, Kumar V.

Immunol Rev. 1998 Oct;165:47-61. Review.

PMID:
9850851
21.

Ontogeny and differentiation of murine natural killer cells and their receptors.

Sivakumar PV, Puzanov I, Williams NS, Bennett M, Kumar V.

Curr Top Microbiol Immunol. 1998;230:161-90. Review. No abstract available.

PMID:
9586356
23.
24.

NK cell lines of different maturational status can be obtained from mouse foetal liver.

Manoussaka M, Georgiou A, Rossiter B, Shrestha S, Toomey JA, Sivakumar PV, Bennett M, Kumar V, Brooks CG.

Biochem Soc Trans. 1997 May;25(2):174S. No abstract available.

PMID:
9191218
25.

Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in?

Puzanov IJ, Williams NS, Schatzle J, Sivakumar PV, Bennett M, Kumar V.

Res Immunol. 1997 Mar-Apr;148(3):195-201. Review. No abstract available.

PMID:
9255874
26.

Phenotypic and functional characterization of long-lived NK cell lines of different maturational status obtained from mouse fetal liver.

Manoussaka M, Georgiou A, Rossiter B, Shrestha S, Toomey JA, Sivakumar PV, Bennett M, Kumar V, Brooks CG.

J Immunol. 1997 Jan 1;158(1):112-9.

PMID:
8977181

Supplemental Content

Loading ...
Support Center